{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:53:43Z","timestamp":1788292423564,"version":"build-2803163510"},"reference-count":219,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The high recurrence rate of non-muscle invasive bladder cancer (BC) and poor prognosis of advanced BC are therapeutic challenges that need to be solved. Bacillus Calmette-Guerin (BCG) perfusion was the pioneer immunotherapy for early BC, and the discovery of immune checkpoint inhibitors has created a new chapter in the treatment of advanced BC. The benefit of immunotherapy is highly anticipated, but its effectiveness still needs to be improved. In this review, we collated and analysed the currently available information and explored the mechaisms by which the internal immune imbalance of BC leads to tumour progression. The relationship between immunity and progression and the prognosis of BC has been explored through tests using body fluids such as blood and urine. These analytical tests have attempted to identify specific immuyne cells and cytokines to predict treatment outcomes and recurrence. The diversity and proportion of immune and matrix cells in BC determine the heterogeneity and immune status of tumours. The role and classification of immune cells have also been redefined, e.g., CD4 cells having recognised cytotoxicity in BC. Type 2 immunity, including that mediated by M2 macrophages, Th2 cells, and interleukin (IL)-13, plays an important role in the recurrence and progression of BC. Pathological fibrosis, activated by type 2 immunity and cancer cells, enhances the rate of cancer progression and irreversibility. Elucidating the immune status of BC and clarifying the mechanisms of action of different cells in the tumour microenvironment is the research direction to be explored in the future.<\/jats:p>","DOI":"10.3389\/fimmu.2022.963877","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T04:39:25Z","timestamp":1662611965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Immune status for monitoring and treatment of bladder cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Shen","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: An update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/551S33a","article-title":"Bladder cancer","volume":"551","author":"Grayson","year":"2017","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/s1470-2045(20)30586-6","article-title":"Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer","volume":"22","author":"Kulkarni","year":"2021","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ccell.2018.07.013","article-title":"SnapShot: Bladder cancer","volume":"34","author":"Hurst","year":"2018","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71167-2","article-title":"Anti-PD-L1 antibody active in metastatic bladder cancer","volume":"16","author":"Brower","year":"2015","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30242-x","article-title":"Anti-PD-L1 inhibitor durvalumab in bladder cancer","volume":"17","author":"Brower","year":"2016","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30433-9","article-title":"EMA restricts use of anti-PD-1 drugs for bladder cancer","volume":"19","author":"Gourd","year":"2018","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jnci\/djaa076","article-title":"Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"113","author":"Bandini","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.10.004","article-title":"Clinical outcome after progressing to frontline and second-line anti-PD-1\/PD-L1 in advanced urothelial cancer","volume":"77","author":"G\u00f3mez de Lia\u00f1o Lista","year":"2020","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.05.037","article-title":"Programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: A systematic review and meta-analysis","volume":"76","author":"Niglio","year":"2019","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.10650","article-title":"Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer","volume":"322","author":"Parikh","year":"2019","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1001\/jama.2017.6976","article-title":"Immunotherapy for bladder cancer","volume":"317","author":"Voelker","year":"2017","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"ITP-CAoWG. Pan-cancer analysis of whole genomes","volume":"578","year":"2020","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41590-019-0549-0","article-title":"High-throughput phenotyping reveals expansive genetic and structural underpinnings of immune variation","volume":"21","author":"Abeler-D\u00f6rner","year":"2020","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/ng.2825","article-title":"Taking pan-cancer analysis global","volume":"45","year":"2013","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.042","article-title":"The cancer genome atlas: Creating lasting value beyond its data","volume":"173","author":"Hutter","year":"2018","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature16064","article-title":"Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer","volume":"527","author":"Zheng","year":"2015","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01101","article-title":"Bladder cancer exhibiting high immune infiltration shows the lowest response rate to immune checkpoint inhibitors","volume":"91101","author":"Pan","year":"2019","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29939","article-title":"Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression","volume":"236","author":"Liu","year":"2021","journal-title":"J Cell Physiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13113","article-title":"Biodistribution of Evans blue in an orthotopic AY-27 rat bladder urothelial cell carcinoma model: Implication for the improved diagnosis of non-muscle-invasive bladder cancer (NMIBC) using dye-guided white-light cystoscopy","volume":"116","author":"Elsen","year":"2015","journal-title":"BJU Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/toxins9100310","article-title":"The influence of resiniferatoxin (RTX) and tetrodotoxin (TTX) on the distribution, relative frequency, and chemical coding of noradrenergic and cholinergic nerve fibers supplying the porcine urinary bladder wall","volume":"9","author":"Lepiarczyk","year":"2017","journal-title":"Toxins (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.02.013","article-title":"Role of the innate immune system in the development, progression, and therapeutic response of bladder cancer","volume":"6","author":"Daza","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112043","article-title":"Innate immune recognition of cancer","volume":"33","author":"Woo","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04046-0","article-title":"Inflammation and cancer: Back to virchow","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12885-018-4389-3","article-title":"Reduction of MHC-I expression limits T-lymphocyte-mediated killing of cancer-initiating cells","volume":"18","author":"Morrison","year":"2018","journal-title":"BMC Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.01.015","article-title":"Cancer metabolism drives a stromal regenerative response","volume":"29","author":"Schw\u00f6rer","year":"2019","journal-title":"Cell Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1794-y","article-title":"Patch repair of deep wounds by mobilized fascia","volume":"576","author":"Correa-Gallegos","year":"2019","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00302-5","article-title":"TGF-\u03b21-mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in gastrointestinal stromal tumor","volume":"10","author":"Yoon","year":"2021","journal-title":"Oncogenesis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01663-2","article-title":"Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression","volume":"40","author":"Butti","year":"2021","journal-title":"Oncogene"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00630","article-title":"Fibroblast reprogramming in gastrointestinal cancer","volume":"8630","author":"Melissari","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13046-019-1277-x","article-title":"Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905301116","article-title":"Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology","volume":"116","author":"Nayar","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal PDL1 in tumour immune evasion","volume":"20","author":"Daassi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020712-163930","article-title":"Host responses in tissue repair and fibrosis","volume":"8","author":"Duffield","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","article-title":"CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.cell.2020.03.013","article-title":"SnapShot: Cancer-associated fibroblasts","volume":"181","author":"Park","year":"2020","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T Cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B56","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/jci45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"145451","DOI":"10.1016\/j.gene.2021.145451","article-title":"Cancer-associated fibroblasts and the related runt-related transcription factor 2 (RUNX2) promote bladder cancer progression","volume":"775","author":"Liu","year":"2021","journal-title":"Gene"},{"key":"B59","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12935-021-01896-x","article-title":"The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer","volume":"21","author":"Du","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B60","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41598-019-55013-0","article-title":"Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome","volume":"10","author":"Mezheyeuski","year":"2020","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2019.07.002","article-title":"The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5\/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder","volume":"91","author":"Calvete","year":"2019","journal-title":"Hum Pathol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41419-019-1581-6","article-title":"Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1\/ER\u03b2\/Bcl-2 signalling","volume":"10","author":"Long","year":"2019","journal-title":"Cell Death Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J Exp Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0170","article-title":"Post-sepsis state induces tumor-associated macrophage accumulation through CXCR4\/CXCL12 and favors tumor progression in mice","volume":"4","author":"Mota","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00949-7","article-title":"Not-so-opposite ends of the spectrum: CD8(+) T cell dysfunction across chronic infection, cancer and autoimmunity","volume":"22","author":"Collier","year":"2021","journal-title":"Nat Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0223-7","article-title":"Precursor exhausted T cells: key to successful immunotherapy","volume":"20","author":"Kallies","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8(+) T cell metabolism in infection and cancer","volume":"21","author":"Reina-Campos","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/cancers12092692","article-title":"Prognostic and predictive value of tumor-infiltrating immune cells in urothelial cancer of the bladder","volume":"12","author":"van Wilpe","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000978","article-title":"Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-18-0725","article-title":"Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0345-y","article-title":"Thymic development of unconventional T cells: how NKT cells, MAIT cells and \u03b3\u03b4 T cells emerge","volume":"20","author":"Pellicci","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2523","article-title":"Transcriptional reprogramming of mature CD4+ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes","volume":"14","author":"Mucida","year":"2013","journal-title":"Nat Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1240","article-title":"Role for IL-10 in suppression mediated by peptide-induced regulatory T cells","volume":"170","author":"Sundstedt","year":"2003","journal-title":"vivo. J Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) t(reg) cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10020.x","article-title":"FOXP3 and survival in urinary bladder cancer","volume":"108","author":"Winerdal","year":"2011","journal-title":"BJU Int"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02583-y","article-title":"CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer","volume":"69","author":"Wang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1621280114","article-title":"CCR8(+)FOXp3(+) t(reg) cells as master drivers of immune regulation","volume":"114","author":"Barsheshet","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.004","article-title":"Chemokines and cancer: new immune checkpoints for cancer therapy","volume":"51","author":"Karin","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.immuni.2021.03.007","article-title":"Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells","volume":"54","author":"Delacher","year":"2021","journal-title":"Immunity"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1215-2","article-title":"Targeting the CBM complex causes t(reg) cells to prime tumours for immune checkpoint therapy","volume":"570","author":"Di Pilato","year":"2019","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/path.4133","article-title":"Macrophage plasticity and polarization in tissue repair and remodelling","volume":"229","author":"Mantovani","year":"2013","journal-title":"J Pathol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.11.7405","article-title":"Expression of tie-2 by human monocytes and their responses to angiopoietin-2","volume":"178","author":"Murdoch","year":"2007","journal-title":"J Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4392","article-title":"Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness","volume":"11","author":"Takeuchi","year":"2016","journal-title":"Oncol Lett"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.609334","article-title":"M2 macrophage Co-expression factors correlate with immune phenotype and predict prognosis of bladder cancer","volume":"11609334","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-19-2254","article-title":"Blockade of DC-SIGN(+) tumor-associated macrophages reactivates antitumor immunity and improves immunotherapy in muscle-invasive bladder cancer","volume":"80","author":"Hu","year":"2020","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.10.009","article-title":"Immunoregulation of dendritic cell subsets by inhibitory receptors in urothelial cancer","volume":"71","author":"Chevalier","year":"2017","journal-title":"Eur Urol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"15776","DOI":"10.1038\/ncomms15776","article-title":"IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours","volume":"8","author":"Seo","year":"2017","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/cyt.12661","article-title":"Liquid biopsy: A new avenue in pathology","volume":"30","author":"Ghosh","year":"2019","journal-title":"Cytopathology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1001\/jama.2020.9266","article-title":"Blood test flags multiple cancers in Large study","volume":"323","author":"Abbasi","year":"2020","journal-title":"Jama"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.360.6396.1387","article-title":"Blood test may predict cancer immunotherapy benefit","volume":"360","author":"Garber","year":"2018","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/science.359.6373.259","article-title":"\u2018Liquid biopsy\u2019 for cancer promises early detection","volume":"359","author":"Kaiser","year":"2018","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/science.368.6490.461","article-title":"Cancer DNA blood test gets real-world trial","volume":"368","author":"Kaiser","year":"2020","journal-title":"Science"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9601","article-title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention","volume":"369","author":"Lennon","year":"2020","journal-title":"Science"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.10.724","article-title":"Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer","volume":"89","author":"Kinoshita","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.046","article-title":"Extracellular vesicles and their role in urologic malignancies","volume":"70","author":"Junker","year":"2016","journal-title":"Eur Urol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2015.281","article-title":"Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA","volume":"24","author":"Togneri","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00899-0","article-title":"Extracellular vesicles in immunomodulation and tumor progression","volume":"22","author":"Marar","year":"2021","journal-title":"Nat Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41568-020-00299-w","article-title":"The evolving translational potential of small extracellular vesicles in cancer","volume":"20","author":"M\u00f6ller","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"B112","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cell.2019.09.005","article-title":"SnapShot: The RNA exosome","volume":"179","author":"Puno","year":"2019","journal-title":"Cell"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1704286","article-title":"Circulating extracellular vesicles in human disease","volume":"379","author":"Shah","year":"2018","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21650","article-title":"Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions","volume":"71","author":"Cheng","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1159\/000474509","article-title":"T Lymphocytes infiltrating the bladder wall of patients with carcinoma of urinary bladder are in vivo activated","volume":"31","author":"Reyes","year":"1997","journal-title":"Eur Urol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181003","article-title":"Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment","volume":"215","author":"Wong","year":"2018","journal-title":"J Exp Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer","volume":"181","author":"Bisiaux","year":"2009","journal-title":"J Urol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus calmette-guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus calmette-gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1172\/jci80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1172\/jci80006","article-title":"Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J Clin Invest"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1172\/jci89717","article-title":"ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence","volume":"127","author":"Chevalier","year":"2017","journal-title":"J Clin Invest"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus calmette-gu\u00e9rin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus calmette-gu\u00e9rin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3390\/ijms18102186","article-title":"Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille calmette-gu\u00e9rin: A long-term follow-up study of a Japanese cohort","volume":"18","author":"Miyake","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3485","article-title":"FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS","volume":"20","author":"Liu","year":"2014","journal-title":"Nat Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S165840","article-title":"Bacillus calmette-gu\u00e9rin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA Approval summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20170051","article-title":"ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control","volume":"214","author":"Schwartz","year":"2017","journal-title":"J Exp Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.651745","article-title":"Three vs. four cycles of neoadjuvant chemotherapy for localized muscle invasive bladder cancer undergoing radical cystectomy: A retrospective multi-institutional analysis","volume":"11651745","author":"Ferro","year":"2021","journal-title":"Front Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000002190","article-title":"Identifying the optimal number of neoadjuvant chemotherapy cycles in patients with muscle invasive bladder cancer","volume":"207","author":"D\u2019Andrea","year":"2022","journal-title":"J Urol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1172\/jci147025","article-title":"FOXA1 overexpression suppresses interferon signaling and immune response in cancer","volume":"131","author":"He","year":"2021","journal-title":"J Clin Invest"},{"key":"B149","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.048","article-title":"Neoadjuvant chemotherapy reinforces antitumour T cell response in urothelial urinary bladder cancer","volume":"74","author":"Krantz","year":"2018","journal-title":"Eur Urol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3735","article-title":"The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer","volume":"13","author":"Vollmer","year":"2021","journal-title":"Sci Transl Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.033","article-title":"Inflammatory biomarkers and bladder cancer prognosis: a systematic review","volume":"66","author":"Masson-Lecomte","year":"2014","journal-title":"Eur Urol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1159\/000506263","article-title":"Impact of routine laboratory parameters in patients undergoing radical cystectomy for urothelial carcinoma of the bladder: A long-term follow-up","volume":"104","author":"Tamalunas","year":"2020","journal-title":"Urol Int"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03482-8","article-title":"Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy","volume":"39","author":"Rodler","year":"2021","journal-title":"World J Urol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-2776(08)60379-x","article-title":"Acute phase proteins with special reference to c-reactive protein and related proteins (pentaxins) and serum amyloid a protein","volume":"34","author":"Pepys","year":"1983","journal-title":"Adv Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-291x(88)80043-3","article-title":"Role of interleukin-6 in regulating synthesis of c-reactive protein and serum amyloid a in human hepatoma cell lines","volume":"157","author":"Ganapathi","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"B159","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1084\/jem.189.3.599","article-title":"C-reactive protein: a physiological activator of interleukin 6 receptor shedding","volume":"189","author":"Jones","year":"1999","journal-title":"J Exp Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744129","article-title":"C-reactive protein and cancer: Interpreting the differential bioactivities of its pentameric and monomeric, modified isoforms","volume":"12744129","author":"Potempa","year":"2021","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B163","doi-asserted-by":"publisher","first-page":"483.e417","DOI":"10.1016\/j.urolonc.2016.05.013","article-title":"Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer","volume":"34","author":"Mbeutcha","year":"2016","journal-title":"Urol Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1680-7","article-title":"Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study","volume":"34","author":"Grimm","year":"2016","journal-title":"World J Urol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10234.x","article-title":"Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum c-reactive protein and standard pathological risk factors: the TNR-c score","volume":"108","author":"Gakis","year":"2011","journal-title":"BJU Int"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys124","article-title":"Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer","volume":"42","author":"Hwang","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07408.x","article-title":"C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy","volume":"101","author":"Yoshida","year":"2008","journal-title":"BJU Int"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11153.x","article-title":"Impact of c-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin","volume":"110","author":"Saito","year":"2012","journal-title":"BJU Int"},{"key":"B169","article-title":"Activation of human monocyte tumoricidal activity by c-reactive protein","volume":"47","author":"Barna","year":"1987","journal-title":"Cancer Res"},{"key":"B170","article-title":"Macrophage tumoricidal activity induced by human c-reactive protein","volume":"46","author":"Zahedi","year":"1986","journal-title":"Cancer Res"},{"key":"B171","article-title":"Macrophage activation and generation of tumoricidal activity by liposome-associated human c-reactive protein","volume":"44","author":"Barna","year":"1984","journal-title":"Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2455","article-title":"Cancer as an overhealing wound: an old hypothesis revisited","volume":"9","author":"Sch\u00e4fer","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-based network analysis reveals a spectrum model of human macrophage activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"key":"B175","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2009.06.018","article-title":"CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages","volume":"16","author":"DeNardo","year":"2009","journal-title":"Cancer Cell"},{"key":"B176","doi-asserted-by":"publisher","first-page":"105880","DOI":"10.1016\/j.intimp.2019.105880","article-title":"A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting","volume":"76","author":"Sharifi","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1541-7786.Mcr-12-0274","article-title":"Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma","volume":"10","author":"van der Horst","year":"2012","journal-title":"Mol Cancer Res"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.08.027","article-title":"Molecular subtypes of urothelial bladder cancer: Results from a meta-cohort analysis of 2411 tumors","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-1004","article-title":"BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer","volume":"23","author":"Mart\u00ednez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-2230","article-title":"Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction","volume":"26","author":"Kobatake","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2016.08.006","article-title":"Tissue-specific contribution of macrophages to wound healing","volume":"61","author":"Minutti","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095906","article-title":"Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: Roles in homeostasis and disease","volume":"31","author":"Van Dyken","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052350","article-title":"Th2 cells in health and disease","volume":"35","author":"Nakayama","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/ijms20092159","article-title":"Dendritic cell-mediated Th2 immunity and immune disorders","volume":"20","author":"Kumar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-08-0449","article-title":"Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.23","article-title":"The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling","volume":"6","author":"Nappo","year":"2017","journal-title":"Oncogenesis"},{"key":"B188","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.10.008","article-title":"Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer","volume":"59","author":"Margel","year":"2011","journal-title":"Eur Urol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.2.1021","article-title":"Eosinophils express functional IL-13 in eosinophilic inflammatory diseases","volume":"169","author":"Schmid-Grendelmeier","year":"2002","journal-title":"J Immunol"},{"key":"B191","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.142.2.679","article-title":"A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes","volume":"142","author":"Brown","year":"1989","journal-title":"J Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/82771","article-title":"NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway","volume":"1","author":"Terabe","year":"2000","journal-title":"Nat Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.1.250","article-title":"Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and reed-sternberg cells of Hodgkin lymphoma","volume":"97","author":"Skinnider","year":"2001","journal-title":"Blood"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.12.1939","article-title":"Interleukin 13 is secreted by and stimulates the growth of Hodgkin and reed-sternberg cells","volume":"189","author":"Kapp","year":"1999","journal-title":"J Exp Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba2374","article-title":"Preventing engrailed-1 activation in fibroblasts yields wound regeneration without scarring","volume":"372","author":"Mascharak","year":"2021","journal-title":"Science"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2021.02.004","article-title":"Distinct regulatory programs control the latent regenerative potential of dermal fibroblasts during wound healing","volume":"28","author":"Abbasi","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B197","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cell.2020.06.030","article-title":"Type V collagen in scar tissue regulates the size of scar after heart injury","volume":"182","author":"Yokota","year":"2020","journal-title":"Cell"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.08.007","article-title":"Moving on after trauma: Fibroblasts thrive in the right environment","volume":"27","author":"Ramos","year":"2020","journal-title":"Cell Stem Cell"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.08.015","article-title":"Molecular landscape of non-muscle invasive bladder cancer","volume":"32","author":"Meeks","year":"2017","journal-title":"Cancer Cell"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-17-0784","article-title":"Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGF\u03b2 signaling","volume":"16","author":"Ringuette Goulet","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.09.006","article-title":"Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p","volume":"36","author":"Li","year":"2018","journal-title":"EBioMedicine"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.33750","article-title":"Exosomal miRNA-139 in cancer-associated fibroblasts inhibits gastric cancer progression by repressing MMP11 expression","volume":"15","author":"Xu","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.03.004","article-title":"Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis","volume":"397","author":"Zhang","year":"2017","journal-title":"Cancer Lett"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2275","article-title":"FDA Approval summary: Enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1782201","article-title":"The emerging role of antibody-drug conjugates in urothelial carcinoma","volume":"20","author":"Lattanzi","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00446","article-title":"Perspective: Designing T-cell engagers with better therapeutic windows","volume":"10446","author":"Vafa","year":"2020","journal-title":"Front Oncol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.7150\/jca.29937","article-title":"Targeting immunotherapy for bladder cancer by using anti-CD3 \u00d7 CD155 bispecific antibody","volume":"10","author":"Ma","year":"2019","journal-title":"J Cancer"},{"key":"B208","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","article-title":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","volume":"7","author":"Kvarnhammar","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1778-6","article-title":"Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model","volume":"17","author":"Furuya","year":"2019","journal-title":"J Transl Med"},{"key":"B210","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-019-0551-y","article-title":"Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy","volume":"7","author":"Knudson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672262","article-title":"Treating bladder cancer: Engineering of current and next generation antibody-, fusion protein-, mRNA-, cell- and viral-based therapeutics","volume":"11672262","author":"Bogen","year":"2021","journal-title":"Front Oncol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/nri3831","article-title":"Type 2 cytokines: mechanisms and therapeutic strategies","volume":"15","author":"Wynn","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1128\/cmr.05040-11","article-title":"Helminth infections and host immune regulation","volume":"25","author":"McSorley","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-012-0354-4","article-title":"Th2 responses in schistosomiasis","volume":"34","author":"Fairfax","year":"2012","journal-title":"Semin Immunopathol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.2174\/156652408785161023","article-title":"Airway fibrosis and angiogenesis due to eosinophil trafficking in chronic asthma","volume":"8","author":"Aceves","year":"2008","journal-title":"Curr Mol Med"},{"key":"B216","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5858\/134.1.27","article-title":"Respiratory bronchiolitis\/interstitial lung disease: fibrosis, pulmonary function, and evolving concepts","volume":"134","author":"Churg","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1002\/path.4733","article-title":"Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-\u03b3","volume":"239","author":"Ramalingam","year":"2016","journal-title":"J Pathol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"301ra129","DOI":"10.1126\/scitranslmed.aab3142","article-title":"TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma","volume":"7","author":"Choy","year":"2015","journal-title":"Sci Transl Med"},{"key":"B219","doi-asserted-by":"publisher","first-page":"e004427","DOI":"10.1136\/jitc-2021-004427","article-title":"Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.963877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T11:48:37Z","timestamp":1676720917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.963877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":219,"alternative-id":["10.3389\/fimmu.2022.963877"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.963877","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"article-number":"963877"}}